Hu, Zhiwei http://orcid.org/0000-0002-0023-1170
Cheng, Jijun
Xu, Jie
Ruf, Wolfram
Lockwood, Charles J.
Funding for this research was provided by:
State of Connecticut Department of Public Health (2009-0096)
National Center for Advancing Translational Sciences (UL1TR001070)
Article History
Received: 19 July 2016
Accepted: 25 October 2016
First Online: 2 November 2016
Compliance with ethical standards
:
: Z.H. is co-inventor of US patents on neovascular-targeted immunoconjugates (ICON) and is co-inventor of two US patent applications on “Factor VII conjugates for selectively treating neovascularization disorders.” W.R. is currently serving as a consultant for Iconic Therapeutics, a startup biotech based on ICON patents. Other authors declare no conflict of interest.